We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques.
- Authors
Solforosi, Laura; Costes, Lea M. M.; Tolboom, Jeroen T. B. M.; McMahan, Katherine; Anioke, Tochi; Hope, David; Murdza, Tetyana; Sciacca, Michaela; Bouffard, Emily; Barrett, Julia; Wu, Cindy; Hachmann, Nicole; Miller, Jessica; Yu, Jingyou; He, Xuan; Jacob-Dolan, Catherine; Huber, Sietske K. Rosendahl; Dekking, Liesbeth; Chamanza, Ronnie; Choi, Ying
- Abstract
Omicron spike (S) encoding vaccines as boosters, are a potential strategy to improve COVID-19 vaccine efficacy against Omicron. Here, macaques (mostly females) previously immunized with Ad26.COV2.S, are boosted with Ad26.COV2.S, Ad26.COV2.S.529 (encoding Omicron BA.1 S) or a 1:1 combination of both vaccines. All booster vaccinations elicit a rapid antibody titers increase against WA1/2020 and Omicron S. Omicron BA.1 and BA.2 antibody responses are most effectively boosted by vaccines including Ad26.COV2.S.529. Independent of vaccine used, mostly WA1/2020-reactive or WA1/2020-Omicron BA.1 cross-reactive B cells are detected. Ad26.COV2.S.529 containing boosters provide only slightly higher protection of the lower respiratory tract against Omicron BA.1 challenge compared with Ad26.COV2.S-only booster. Antibodies and cellular immune responses are identified as complementary correlates of protection. Overall, a booster with an Omicron-spike based vaccine provide only moderately improved immune responses and protection compared with the original Wuhan-Hu-1-spike based vaccine, which still provide robust immune responses and protection against Omicron. Variant booster vaccines are a strategy to improve protection against SARS-CoV-2. Here, the authors find that both Wuhan-Hu-1-based Ad26.COV2.S or an Omicron-adapted booster vaccine provide robust immune responses and protection against Omicron in NHP.
- Subjects
SARS-CoV-2 Omicron variant; BOOSTER vaccines; SARS-CoV-2; MACAQUES; COMBINED vaccines; IMMUNOGLOBULINS; B cells; B cell receptors
- Publication
Nature Communications, 2023, Vol 14, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-023-37715-2